Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Lannett Company $350 million senior secured notes offering
We advised the initial purchasers on the high-yield notes offering
Akoya Biosciences $151.3 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Recursion Pharmaceuticals $500 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Diagnósticos da América R$3.3 billion equity offering
We advised the global coordinators and joint bookrunners on the Rule 144A / Regulation S offering
Ionis Pharmaceuticals $632.5 million convertible senior notes offering
We advised the purchasers on the Rule 144A convertible notes offering
Maravai LifeSciences $646.9 million secondary offering
We advised the joint book-running managers on the equity offering
Beam Therapeutics $300 million at-the-market offering
We advised the sales agent in connection with the equity offering
Alignment Healthcare $489.6 million IPO
We advised the underwriters on the IPO and Nasdaq listing
LAVA Therapeutics $100.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Gyroscope Therapeutics $148.0 million Series C equity financing
We advised Gyroscope Therapeutics on its private placement of preferred stock